

NOTICE OF CHANGE IN CORPORATE STRUCTURE

Pursuant to Section 4.9 of National Instrument 51-102 Continuous Disclosure Obligations

Item 1 Names of the Parties to the Transaction

Noveris Health Sciences Inc.
(Mydecine Innovations Group Inc. (the “**Company**”))

Item 2 Description of the Transaction

On February 2, 2026, the Company changed its name from “Mydecine Innovations Group Inc.” to “Noveris Health Sciences Inc.”

Effective at the opening of markets on February 2, 2026, the Company commenced trading of its common shares on the Canadian Securities Exchange (the “**CSE**”) under the new name: Noveris Health Sciences Inc. and the stock symbol “**NVRS**”.

The Company’s new CUSIP number is 66990B108 and the new ISIN number is CA66990B1085.

There were no other changes in the corporate structure of the Company, and there was no change to the Company’s financial year-end or interim and annual reporting periods.

Item 3 Effective Date of the Transaction

February 2, 2026.

Item 4 Names of Each Party, if any, that Ceased to be a Reporting Issuer after the Transaction and of each Continuing Entity

Not Applicable.

Item 5 Date of the Reporting Issuer’s First Financial Year-End after the Transaction, if applicable

Not Applicable.

Item 6 The Periods, including comparative periods, if any, of the Interim and Annual Financial Statements Required to be Filed for the Reporting Issuer’s First Financial Year after the Transaction, if applicable

Not Applicable.

Item 7. Documents filed under NI 51-102 that describe the Transaction

On February 6, 2026, the Company filed a material change report on SEDAR.

On February 2, 2026, the Company filed the Certificate of Change of Name on SEDAR.

On January 29, 2026, the Company disseminated and filed on SEDAR a news release announcing the effective date of the change of name.